Request Study Information

After you submit your request, a staff member will contact you.There’s no obligation and our team is here to help you decide on a study that’s best for you.

A Phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaLuate the effIcacy and safety of abeLacimab in high-risk patients with Atrial fibrillation who have been deemed unsuitable for oral antiCoagulation (LILAC)

Enter Your Information

(All fields are required)

Study Request Form (specific)

Name(Required)

First Name Last Name

Phone Number(Required)

Email Address(Required)

Date of Birth(Required)

Gender(Required)

Preferred Location(Required)

Study Of Interest(Required)

Preferred Language(Required)

Are you Hispanic or Latino(Required)

Race(Required)

Select one or more options that best describe you. This information can help ensure that all populations are represented in research.

American Indian or Alaskan Native

Asian

Black or African American

Native Hawaiian or Other Pacific Islander

White or Caucasian

By entering your email address and/or phone number on this form, you represent that you are at least 18 years of age and consent to receiving communications (e.g., call, SMS, text, and/or email) from ECIR and/or the research site(s) involved with the clinical trials that appear on this website. Messaging frequency varies. Message and data rates may apply. You may reply with STOP to a text message. For any help regarding messaging, please email us at [email protected]. For full details, refer to ECIR’s privacy policy and website terms of use. Submissions on this website are not monitored 24/7. Do NOT submit personal health or medical information on this form. If you are enrolled in a trial and have questions, please call your research site.

CAPTCHA